Comparing 3-year survival and readmissions between HeartMate 3 and heart transplant as primary treatment for advanced heart failure

Kirschner, M., Topkara, V. K., Sun, J., Kurlansky, P., Kaku, Y., Naka, Y., Yuzefpolskaya, M., Colombo, P. C., Sayer, G., Uriel, N., & Takeda, K. (2023). Comparing 3-year survival and readmissions between HeartMate 3 and heart transplant as primary treatment for advanced heart failure. The Journal of Thoracic and Cardiovascular Surgery. https://doi.org/10.1016/j.jtcvs.2023.12.019
Authors:
Michael Kirschner
Veli K Topkara
Jocelyn Sun
Paul Kurlansky
Yuji Kaku
Yoshifumi Naka
Melana Yuzefpolskaya
Paolo C Colombo
Gabriel Sayer
Nir Uriel
Koji Takeda
Affiliated Authors:
Michael Kirschner
Veli K Topkara
Jocelyn Sun
Paul Kurlansky
Yuji Kaku
Yoshifumi Naka
Melana Yuzefpolskaya
Paolo C Colombo
Gabriel Sayer
Nir Uriel
Koji Takeda
Columbia Affiliation:
Author Keywords:
left ventricular assist device
heart transplant
survival
age
readmissions
elink
Publication Type:
Article
Unique ID:
10.1016/j.jtcvs.2023.12.019
PMID:
38154500
DOI:
10.1016/j.jtcvs.2023.12.019
Journal:
Journal of Thoracic and Cardiovascular Surgery
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Web of Science Record
View Scopus Record

Record Created: